Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial

第2/3相 完了 NCT04075331

概要

This is a single-centre, double-blinded, randomised, placebo controlled trial comparing mepolizumab 100mg versus placebo in patients with eosinophilic COPD, started following their index admission to hospital.

Time From Randomisation to Next Hospital Readmission or Death (All Cause)

Patients were followed up for up to 48 weeks (an absolute maximum of 49 weeks as the 48 week visit had a visit window of +- 1 week). · Weeks

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

• Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and — University of Tennessee Graduate School of Medicine
• Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster — Chiesi Farmaceutici S.p.A.
• Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®T — Chiesi Farmaceutici S.p.A.
• Tiotropium/Salmeterol Inhalation Powder in COPD — Boehringer Ingelheim
• Risk Factors, Costs, and Impacts of ED Boarding — University of Maryland, Baltimore
• Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructiv — United Therapeutics

すべての治験